Table 1.
Main characteristics of all included studies.
| Trials | Year | Country | Sample size | Treatment | HR for OS (95% CI) | HR for RFS (95% CI) | HR for PFS (95% CI) | NOS | References |
|---|---|---|---|---|---|---|---|---|---|
| Bruna (STAT3) | 2016 | Brazil | 85 | Nonstandard | 1.050 (0.540-2.040) | 2.560 (0.006-110.040) | NA | 8 | [50] |
| Bruna (pSTAT3-Tyr705) | 2016 | Brazil | 85 | Nonstandard | 0.850 (0.520-1.390) | 0.380 (0.120-1.190) | NA | 8 | [50] |
| Bruna (pSTAT3-Ser727) | 2016 | Brazil | 85 | Nonstandard | 0.990 (0.590-1.670) | 0.290 (0.050-1.470) | NA | 8 | [50] |
| Lin (pSTAT3-Tyr705) | 2014 | China | 90 | Nonstandard | 2.120 (1.070-4.203) | NA | 2.158 (1.136-4.098) | 8 | [44] |
| Lin (pSTAT3-Ser727) | 2014 | China | 88 | Nonstandard | 1.797 (1.028-3.142) | NA | 1.830 (1.090-3.074) | 9 | [45] |
| Liang (STAT3) | 2013 | China | 68 | Nonstandard | 1.480 (0.460-4.730) | NA | 1.850 (0.530-6.520) | 9 | [51] |
| Liang (pSTAT3-Tyr705) | 2013 | China | 68 | Nonstandard | 2.301 (1.726-3.021) | NA | 2.001 (1.509-2.877) | 9 | [51] |
| Wang (pSTAT3-Tyr705) | 2011 | China | 68 | Standard | 2.402 (1.268-4.550) | NA | 2.629 (1.362-5.073) | 9 | [46] |
| Piperi (pSTAT3-Tyr705) | 2011 | Greece | 97 | Nonstandard | 0.611 (0.332-1.124) | NA | NA | 9 | [48] |
| Tu (STAT3) | 2011 | China | 96 | Nonstandard | 2.360 (1.370-10.980) | NA | NA | 7 | [43] |
| Birner (pSTAT3-Tyr705) | 2010 | Bulgaria | 111 | Standard | 1.400 (0.790-2.460) | NA | NA | 7 | [47] |
| Mohamed (pSTAT3-Tyr705) | 2008 | America | 129 | Nonstandard | 1.200 (0.640-2.220) | NA | NA | 5 | [49] |
Note: HR: hazard ratio; OS: overall survival; RFS: recurrence-free survival; PFS: progression-free survival; NOS: Newcastle-Ottawa scale; NA: not applicable.